Molecular Diagnostics Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Molecular Diagnostics Market

Molecular Diagnostics Market Size, Share & Trends by Product & Services (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH, INAAT), Application (Infectious (Hepatitis, HIV, HAI, TB, HPV), Oncology) - Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 2521 Jul, 2024, by marketsandmarkets.com

Molecular Diagnostics Market Size, Share & Trends

The size of global molecular diagnostics market in terms of revenue was estimated to be worth $17.3 billion in 2024 and is poised to reach $32.7 billion by 2029, growing at a CAGR of 13.5% from 2024 to 2029. There is an increased focus on funding in the areas of precision medicine and genomics by the government which has amplified the usage of molecular diagnostics-based kits and instruments. Also, the high influx of patients has led to an increasing number of hospitals being established in both developed and emerging economies that is further fuelling the demand for precise molecular based testing. Recent technological developments with respect to portability and quick turnaround times have made it easier for smaller facilities to include molecular based testing into their workflow.

Molecular Diagnostics Market Trends

Molecular Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Molecular Diagnostics Market

Molecular Diagnostics Market Dynamics

DRIVER: Increased investment and emphasis on R&D in molecular diagnostics

Increasing government initiatives, schemes, and funding activities support and promote research and development that enables growth prospects in the molecular diagnostics market. These financial incentives and support mechanisms for companies and research institutes lead to increased investments in R&D, infrastructure, and the development of advanced diagnostic technologies.  For instance, the Bill & Melinda Gates Foundation had awarded funding of USD 14.2 million to LumiraDx Limited (UK) in December 2022 to support the company's further development of a molecular TB point-of-care testing device. Such funding initiatives are expected to support the further growth of the molecular diagnostics market.

RESTRAINT: High cost of molecular diagnostic products

Molecular diagnostic devices are expensive; only big hospitals and reference laboratories with substantial capital budgets may be able to purchase them. Due to their lack of capital budgets, many small laboratories, healthcare clinics, and practitioners might not be able to purchase an analyzer that is very large. Therefore, high costs may limit the growth of the molecular diagnostics market.

OPPORTUNITY: Opportunities for growth in developing economies

Major players in the molecular diagnostics market could see development prospects from emerging economies including South Africa, Brazil, Turkey, Russia, and India. High disease prevalence, a sizable patient base, better healthcare facilities, rising disposable incomes, and an increase in medical tourism are some factors responsible for this. Furthermore, investing heavily in life science research and healthcare in emerging economies is also playing a crucial role in upgrading laboratory infrastructures in these countries. This in turn encourages the installation of diagnostic equipment in labs and contributes to the expanding use of molecular diagnostics.

CHALLENGE: Evolving regulatory environment for IVD and molecular diagnostics

In the US and European nations, there is growing enforcement of strict regulatory and legislative standards pertaining to IVD, especially molecular diagnostics. In the US, medical device regulations apply to IVD products, as stated in 21 CFR 809. According to a distinct IVD Directive 98/79/EC, IVD products are classified and governed differently in the EU than other medical devices.  In the European Union (EU), all medical devices marketed must comply with the Medical Device Regulation (MDR) as of May 26, 2021, by law.  Moreover, it could be necessary to install new software on an existing device, update its software, or make any other adjustments when using new applications. Thus, the market for molecular diagnostics may find it challenging to expand as a result of these regulatory restrictions.

Molecular Diagnostics Ecosystem/Market Map

Molecular Diagnostics Market Ecosystem

The largest share in the molecular diagnostics industry in 2023 was held by the reagents & kits segment, by product & service.

Categorized by product & service, the molecular diagnostics market includes reagents & kits, instruments, and services & software. As of 2023, the largest portion of the market was dominated by the reagents & kits segment. Reagents and kits are often in high demand and widely used because of their adaptability to meet various testing requirements. Additionally, there has been a rise in diagnostic testing because of increased awareness about the importance of early disease diagnosis and preventative healthcare. Moreover, constant technological advancements in the field of molecular diagnostics is fuelling the development of new and enhanced reagents and kits. Such sophisticated reagents and kits provide improved performance and dependability and encourages their broad use and helps the market to expand.

Lab tests segment accounted for the largest share of the molecular diagnostics industry in 2023, by test type.

The molecular diagnostics market is categorized into lab tests and PoC tests, based on test type. In 2023, the lab tests segment emerged as the leading sector in the molecular diagnostics market. Technological developments in diagnostics play a major role in the lab tests segment's market expansion. Molecular diagnostic advancements such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) have significantly improved the sensitivity and specificity of testing for infectious diseases and facilitate efficient treatment and control techniques and enable faster and more precise pathogen detection, promoting market expansion. Furthermore, rigorous validation procedures are used for lab-based molecular diagnostic tests to guarantee their precision, dependability, and clinical applicability, which promotes their acceptance in standard medical practice.

PCR segment dominated the molecular diagnostics industry in 2023, based on technology.

Based on technology, the molecular diagnostics market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies. The polymerase chain reaction (PCR) segment accounted for the largest share of the molecular diagnostics market in 2023. Molecular diagnostics uses PCR technologies for a variety of purposes. The identification and diagnosis of numerous infectious diseases, genetic conditions, and cancer biomarkers are all made possible by this adaptability. The developing qRT-PCR technology, automation of PCR equipment, and expanding applications of PCR in proteomics and genomics are driving the PCR market.

North America accounted for the largest share of the molecular diagnostics industry in 2023.

Categorized into six primary regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries, the molecular diagnostics market witnessed North America taking the forefront in 2023. The substantial portion of the global molecular diagnostics market held by North America is primarily due to the advanced healthcare systems in the US and Canada. The region's commercial health insurance firms' increases in healthcare coverage are also anticipated to have a major impact on the market's expansion. Other factors that are expected to support the growth of the molecular diagnostics market in the region include the increasing adoption of cutting-edge technologies like real-time PCR, INAAT, and other technologies for testing for infectious diseases, cancer, and rare genetic diseases. These technological developments have played a major role in the molecular diagnostics market's expansion in North America.

Molecular Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland). Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US). These players lead the market because of their extensive product portfolios and wide geographic presence.

Scope of the Molecular Diagnostics Industry:

Report Metric

Details

Market Revenue in 2024

$17.3 billion

Projected Revenue by 2029

$32.7 billion

Revenue Rate

Poised to Grow at a CAGR of 13.5%

Market Driver

Increased investment and emphasis on R&D in molecular diagnostics

Market Opportunity

Opportunities for growth in developing economies

This report categorizes the molecular diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service
  • Reagents & Kits
  • Instruments
  • Services & Software
By Test Type
  • Lab Tests
  • PoC Tests
By Sample Type
  • Blood, Serum & Plasma
  • Urine
  • Other Sample Types
By Technology
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Technology
  • DNA Sequencing & Next-generation Sequencing
  • In Situ Hybridization
  • DNA Microarrays
  • Other Technologies
By Application
  • Infectious Disease Diagnostics
    • Hepatitis
      • Hepatitis B
      • Hepatitis C
      • Other Hepatitis Diseases
    • HIV
    • CT/NG
    • HAI
    • HPV
    • Tuberculosis
    • Influenza
    • Other Infectious Diseases
  • Oncology Testing
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Other Cancers
  • Genetic Testing
  • Other Applications
By End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Other End Users
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
  • GCC Countries

Recent Developments of Molecular Diagnostics Industry:

  • In March 2024, Danaher (US) received clearance from the US Food and Drug Administration (FDA) for Xpert Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).
  • In March 2024, bioMérieux (France) received US FDA 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel.
  • In November 2023, F. Hoffmann-La Roche Ltd. (Switzerland) launched the LightCycler PRO System to advance clinical needs in molecular diagnostics and address public health challenges.
  • In April 2023, Illumina, Inc. (US) and Pillar Biosciences Inc. (US) partnered to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products.
  • In May 2023, Hologic announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
 
4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 
    4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 
    4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 
    4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 
    4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 
    4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 
    4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 
    4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 
 
5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
                    5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
                    5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
                    5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
                    5.2.2.2 High cost of molecular diagnostic instruments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing significance of companion diagnostics in drug development process
                    5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
                    5.2.4.2 Operational barriers and shortage of skills across major markets
                    5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
    5.4 PATENT ANALYSIS 
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS 
    5.6 SUPPLY CHAIN ANALYSIS 
    5.7 ECOSYSTEM/MARKET MAP ANALYSIS 
           5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS 
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                    5.9.3.3 India
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
                    5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
    5.13 PESTLE ANALYSIS 
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
           5.15.2 BUYING CRITERIA
    5.16 CASE STUDY ANALYSIS 
 
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 88)
    6.1 INTRODUCTION 
    6.2 REAGENTS & KITS 
           6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
    6.3 INSTRUMENTS 
           6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
    6.4 SERVICES & SOFTWARE 
           6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH
 
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 95)
    7.1 INTRODUCTION 
           7.1.1 PRIMARY NOTES
                    7.1.1.1 Key industry insights
    7.2 LAB TESTS 
           7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
    7.3 POC TESTS 
           7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
 
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 100)
    8.1 INTRODUCTION 
    8.2 BLOOD, SERUM, AND PLASMA 
           8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
    8.3 URINE 
           8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
    8.4 OTHER SAMPLE TYPES 
 
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 104)
    9.1 INTRODUCTION 
           9.1.1 PRIMARY NOTES
                    9.1.1.1 Key industry insights
    9.2 POLYMERASE CHAIN REACTION 
           9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
    9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 
           9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
    9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 
           9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
    9.5 IN SITU HYBRIDIZATION 
           9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
    9.6 DNA MICROARRAYS 
           9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
    9.7 OTHER TECHNOLOGIES 
 
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 114)
     10.1 INTRODUCTION 
     10.2 INFECTIOUS DISEASE DIAGNOSTICS 
             10.2.1 HEPATITIS
                        10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
             10.2.2 HIV
                        10.2.2.1 Increased global prevalence of HIV to propel segment
             10.2.3 CT/NG
                        10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
             10.2.4 HAIS
                        10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
             10.2.5 HPV
                        10.2.5.1 Technological advancements for preventing HPV infections to augment market
             10.2.6 TUBERCULOSIS
                        10.2.6.1 Increasing burden of tuberculosis globally to propel market
             10.2.7 INFLUENZA
                        10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
             10.2.8 OTHER INFECTIOUS DISEASES
     10.3 ONCOLOGY TESTING 
             10.3.1 BREAST CANCER
                        10.3.1.1 Increasing prevalence of breast cancer among females to boost market
             10.3.2 COLORECTAL CANCER
                        10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
             10.3.3 LUNG CANCER
                        10.3.3.1 Increasing research for lung cancer biomarkers to drive market
             10.3.4 PROSTATE CANCER
                        10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
             10.3.5 OTHER CANCERS
     10.4 GENETIC TESTING 
             10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
     10.5 OTHER APPLICATIONS 
     10.6 COVID-19 
             10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
 
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 136)
     11.1 INTRODUCTION 
     11.2 DIAGNOSTIC LABORATORIES 
             11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
     11.3 HOSPITALS & CLINICS 
             11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
     11.4 OTHER END USERS 
 
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 141)
     12.1 INTRODUCTION 
     12.2 NORTH AMERICA 
             12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
             12.2.2 US
                        12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
             12.2.3 CANADA
                        12.2.3.1 High availability of funding for genomics research to fuel market
     12.3 EUROPE 
             12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
             12.3.2 GERMANY
                        12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
             12.3.3 UK
                        12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
             12.3.4 FRANCE
                        12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
             12.3.5 ITALY
                        12.3.5.1 Adoption of advanced diagnostic technologies to support market
             12.3.6 SPAIN
                        12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
             12.3.7 RUSSIA
                        12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
             12.3.8 REST OF EUROPE
     12.4 ASIA PACIFIC 
             12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
             12.4.2 CHINA
                        12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
             12.4.3 JAPAN
                        12.4.3.1 Universal healthcare reimbursement policy to support market
             12.4.4 INDIA
                        12.4.4.1 Increased private & public investments and large patient population to drive market
             12.4.5 AUSTRALIA
                        12.4.5.1 High prevalence of infectious diseases to fuel market
             12.4.6 REST OF ASIA PACIFIC
     12.5 LATIN AMERICA 
             12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
             12.5.2 BRAZIL
                        12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
             12.5.3 MEXICO
                        12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
             12.5.4 REST OF LATIN AMERICA
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
             12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA
 
13 COMPETITIVE LANDSCAPE (Page No. - 219)
     13.1 OVERVIEW 
     13.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
     13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
     13.4 MARKET SHARE ANALYSIS 
             13.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
                        13.4.1.1 Polymerase chain reaction (PCR)
                        13.4.1.2 DNA sequencing and NGS
                        13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
                        13.4.1.4 In situ hybridization (ISH)
             13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
                        13.4.2.1 Infectious diseases
     13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             13.5.1 LIST OF EVALUATED VENDORS
             13.5.2 STARS
             13.5.3 EMERGING LEADERS
             13.5.4 PERVASIVE PLAYERS
             13.5.5 PARTICIPANTS
     13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
     13.7 COMPETITIVE BENCHMARKING 
             13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
     13.8 COMPETITIVE SCENARIO 
             13.8.1 KEY PRODUCT LAUNCHES
             13.8.2 KEY DEALS
 
14 COMPANY PROFILES (Page No. - 235)
     14.1 KEY PLAYERS 
             14.1.1 DANAHER
                        14.1.1.1 Business overview
                        14.1.1.2 Products/Services/Solutions offered
                        14.1.1.3 Recent developments
                        14.1.1.4 MnM view
                                     14.1.1.4.1 Right to win
                                     14.1.1.4.2 Strategic choices
                                     14.1.1.4.3 Weaknesses and competitive threats
             14.1.2 F. HOFFMANN-LA ROCHE LTD.
                        14.1.2.1 Business overview
                        14.1.2.2 Products/Services/Solutions offered
                        14.1.2.3 Recent developments
                        14.1.2.4 MnM view
                                     14.1.2.4.1 Right to win
                                     14.1.2.4.2 Strategic choices
                                     14.1.2.4.3 Weaknesses and competitive threats
             14.1.3 HOLOGIC, INC.
                        14.1.3.1 Business overview
                        14.1.3.2 Products/Services/Solutions offered
                        14.1.3.3 Recent developments
                        14.1.3.4 MnM view
                                     14.1.3.4.1 Right to win
                                     14.1.3.4.2 Strategic choices
                                     14.1.3.4.3 Weaknesses and competitive threats
             14.1.4 ILLUMINA, INC.
                        14.1.4.1 Business overview
                        14.1.4.2 Products/Services/Solutions offered
                        14.1.4.3 Recent developments
                        14.1.4.4 MnM view
                                     14.1.4.4.1 Right to win
                                     14.1.4.4.2 Strategic choices
                                     14.1.4.4.3 Weaknesses and competitive threats
             14.1.5 ABBOTT LABORATORIES
                        14.1.5.1 Business overview
                        14.1.5.2 Products/Services/Solutions offered
                        14.1.5.3 Recent developments
                        14.1.5.4 MnM view
                                     14.1.5.4.1 Right to win
                                     14.1.5.4.2 Strategic choices
                                     14.1.5.4.3 Weaknesses and competitive threats
             14.1.6 BIOMÉRIEUX
                        14.1.6.1 Business overview
                        14.1.6.2 Products/Services/Solutions offered
                        14.1.6.3 Recent developments
             14.1.7 THERMO FISHER SCIENTIFIC INC.
                        14.1.7.1 Business overview
                        14.1.7.2 Products/Services/Solutions offered
                        14.1.7.3 Recent developments
             14.1.8 QIAGEN
                        14.1.8.1 Business overview
                        14.1.8.2 Products/Services/Solutions offered
                        14.1.8.3 Recent developments
             14.1.9 REVVITY
                        14.1.9.1 Business overview
                        14.1.9.2 Products/Services/Solutions offered
                        14.1.9.3 Recent developments
             14.1.10 MYRIAD GENETICS, INC.
                        14.1.10.1 Business overview
                        14.1.10.2 Products/Services/Solutions offered
                        14.1.10.3 Recent developments
             14.1.11 SIEMENS HEALTHINEERS AG
                        14.1.11.1 Business overview
                        14.1.11.2 Products/Services/Solutions offered
                        14.1.11.3 Recent developments
     14.2 OTHER PLAYERS 
             14.2.1 BECTON, DICKINSON AND COMPANY
             14.2.2 GRIFOLS, S.A.
             14.2.3 QUIDELORTHO CORPORATION
             14.2.4 AGILENT TECHNOLOGIES, INC.
             14.2.5 DIASORIN S.P.A.
             14.2.6 EXACT SCIENCES CORPORATION
             14.2.7 GENETIC SIGNATURES
             14.2.8 MDXHEALTH
             14.2.9 HTG MOLECULAR DIAGNOSTICS, INC.
             14.2.10 BIOCARTIS
             14.2.11 TBG DIAGNOSTICS LIMITED
             14.2.12 VELA DIAGNOSTICS
             14.2.13 AMOY DIAGNOSTICS CO., LTD.
             14.2.14 ELITECHGROUP
             14.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
             14.2.16 SAVYON DIAGNOSTICS
             14.2.17 ABACUS DIAGNOSTICA OY
             14.2.18 GENEOMBIO TECHNOLOGIES PVT. LTD.
 
15 APPENDIX (Page No. - 307)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 
 
 
LIST OF TABLES (241 TABLES)
 
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS)
TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 GLOBAL CANCER INCIDENCE, 2020
TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2028 (USD MILLION)
TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 196 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 198 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 199 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 200 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 201 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR PCR, BY KEY PLAYER, 2022
TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR DNA SEQUENCING AND NGS, BY KEY PLAYER, 2022
TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022
TABLE 215 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2022
TABLE 216 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022
TABLE 217 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 218 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 219 COMPANY REGIONAL FOOTPRINT
TABLE 220 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 221 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
TABLE 222 KEY DEALS
TABLE 223 DANAHER: COMPANY OVERVIEW
TABLE 224 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 225 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 226 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 227 ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 228 BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 229 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 230 QIAGEN: COMPANY OVERVIEW
TABLE 231 REVVITY: COMPANY OVERVIEW
TABLE 232 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
TABLE 233 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 234 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
TABLE 235 VELA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 236 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
TABLE 237 ELITECHGROUP: COMPANY OVERVIEW
TABLE 238 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
TABLE 239 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
TABLE 240 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
TABLE 241 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
 
 
LIST OF FIGURES (48 FIGURES)
 
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 7 DATA TRIANGULATION METHODOLOGY
FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028
FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD
FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
FIGURE 34 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
FIGURE 35 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
FIGURE 37 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
FIGURE 38 DANAHER: COMPANY SNAPSHOT (2022)
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
FIGURE 46 REVVITY: COMPANY SNAPSHOT (2022)
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the molecular diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Molecular Diagnostics Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Abbott

General Manager

F. Hoffmann-La Roche Ltd.

Area Sales Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Molecular Diagnostics Market Size: Bottom-Up Approach

Molecular Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Molecular Diagnostics Market Size: Top-Down Approach

Molecular Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global molecular diagnostics market, by product & service, test type, sample type, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall molecular diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Available Customizations

MarketsandMarkets offers the following customizations for this market report.

Country Information

  • Additional country-level analysis of the molecular diagnostics market

Company profiles

  • Additional five company profiles of players operating in the molecular diagnostics market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the molecular diagnostics market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 2521
Published ON
Jul, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback